Assessment of qSOFA in the Latin America Sepsis Institute Database
NCT ID: NCT03158493
Last Updated: 2017-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
8435 participants
OBSERVATIONAL
2016-05-31
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
qSOFA in General Wards: the Accuracy in Diagnosis of Sepsis
NCT02930070
Sepse: Critical Analysis of New Sepse Definitions and Retrospective Evaluation of Sepse Protocol at a Tertiary Hospital in Brazil
NCT03217981
Validation of the Quick Sequential [Sepsis-related] Organ Failure Assessment (qSOFA) in Obstetric Patients
NCT04621539
SEPSIS 3 Critera for Risk Stratification in Emergency Patients
NCT02738164
Implementation of a qSOFA Score in the Emergency Department
NCT04568746
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The case managers were instructed to collect the 3 components of the qSOFA criteria, namely reduced level of consciousness, respiratory rate higher than 22 bpm and systolic blood pressure lower than 100 mmHg). In patients included from the ED, these components were checked at the time of triage. In patients in the wards or in the ICU, the 3 components were considered if presented any time in the 24 hours prior to the diagnosis of sepsis.
Outcomes Primary outcome was hospital mortality. Secondary endpoints included admission to ICU and length of ICU stay of more than 48 hours. A secondary composite outcome was hospital mortality plus ICU length of stay higher than two days (for those admitted to the ICU).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of any of the following organ dysfunction
* Systolic blood pressure \<90 mmHg or mean arterial pressure \<65 mmHg or fall in systolic blood pressure\> 40 mmHg.
* Creatinine\> 2.0 mg / dl or diuresis less than 0.5 ml/kg/h in the last 2 hours OR
* Bilirubin\> 2mg/dl,
* Platelet count\<100,000,
* Lactate\> 2 mmol/dl (or above the reference value),
* Coagulopathy (RNI\> 1.5 or APTT\>60 sec),
* PaO2/FiO2 ratio \<300 or recent or increased O2 need to maintain SpO2\> 90
Exclusion Criteria
* Previous sepsis episode in the same hospital admission
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Latin America Sepsis Institute
UNKNOWN
Federal University of São Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Flavia Ribeiro Machado
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flavia R Machado, MD
Role: PRINCIPAL_INVESTIGATOR
Federal University of São Paulo
References
Explore related publications, articles, or registry entries linked to this study.
Machado FR, Cavalcanti AB, Monteiro MB, Sousa JL, Bossa A, Bafi AT, Dal-Pizzol F, Freitas FGR, Lisboa T, Westphal GA, Japiassu AM, Azevedo LCP; Instituto Latino-Americano de Sepsis network investigators. Predictive Accuracy of the Quick Sepsis-related Organ Failure Assessment Score in Brazil. A Prospective Multicenter Study. Am J Respir Crit Care Med. 2020 Apr 1;201(7):789-798. doi: 10.1164/rccm.201905-0917OC.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00691812.3.0000.5505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.